- Home
- ATHA vs KITT Comparison
ATHA vs KITT Comparison
Compare ATHA & KITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- KITT
- Stock Information
- Founded
- ATHA 2011
- KITT 2014
- Country
- ATHA United States
- KITT United States
- Employees
- ATHA N/A
- KITT N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- KITT Industrial Machinery/Components
- Sector
- ATHA Health Care
- KITT Industrials
- Exchange
- ATHA Nasdaq
- KITT Nasdaq
- Market Cap
- ATHA 14.8M
- KITT 16.4M
- IPO Year
- ATHA 2020
- KITT N/A
- Fundamental
- Price
- ATHA $3.82
- KITT $3.22
- Analyst Decision
- ATHA
- KITT
- Analyst Count
- ATHA 0
- KITT 0
- Target Price
- ATHA N/A
- KITT N/A
- AVG Volume (30 Days)
- ATHA 48.3K
- KITT 785.6K
- Earning Date
- ATHA 11-06-2025
- KITT 11-11-2025
- Dividend Yield
- ATHA N/A
- KITT N/A
- EPS Growth
- ATHA N/A
- KITT N/A
- EPS
- ATHA N/A
- KITT N/A
- Revenue
- ATHA N/A
- KITT $3,082,232.00
- Revenue This Year
- ATHA N/A
- KITT $2,936.06
- Revenue Next Year
- ATHA N/A
- KITT N/A
- P/E Ratio
- ATHA N/A
- KITT N/A
- Revenue Growth
- ATHA N/A
- KITT N/A
- 52 Week Low
- ATHA $2.20
- KITT $2.85
- 52 Week High
- ATHA $8.26
- KITT $54.36
- Technical
- Relative Strength Index (RSI)
- ATHA 62.48
- KITT 51.79
- Support Level
- ATHA $3.61
- KITT $2.92
- Resistance Level
- ATHA $4.04
- KITT $3.58
- Average True Range (ATR)
- ATHA 0.25
- KITT 0.32
- MACD
- ATHA -0.17
- KITT -0.07
- Stochastic Oscillator
- ATHA 14.29
- KITT 40.00
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About KITT Nauticus Robotics Inc.
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.